Log in to search using one of your social media accounts:

 

AIUM to honor ultrasound leaders
The American Institute of Ultrasound in Medicine (AIUM) has announced its 2018...Read more on AuntMinnie.comRelated Reading: AIUM publishes guidance for improving ob/gyn US AIUM: Is MRI really needed after MSK ultrasound? AIUM: Machine learning may aid breast ultrasound reads AIUM: NIH prepares for potential re-emergence of Zika virus AIUM: Contrast US biopsy combo finds high-grade prostate cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 23, 2018 Category: Radiology Source Type: news

MRI-based risk model improves prostate cancer detection
A team of international researchers has successfully tested a risk prediction...Read more on AuntMinnie.comRelated Reading: MRI confirms prostate cancer with lower dose of GBCA Biomarker test could direct MRI use for prostate cancer Luminal water MRI could be best for prostate cancer MRI can replace biopsy for prostate cancer surveillance MRI can help avoid unnecessary prostate cancer biopsies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 23, 2018 Category: Radiology Source Type: news

Fathers Can Pass Ovarian Cancer Risk To Their Daughters
BOSTON (CBS) – A new study finds that a higher risk of ovarian cancer can be passed from father to daughter. Researchers at the Roswell Park Cancer Institute in Buffalo, NY looked at data from the Familial Ovarian Cancer Registry and discovered a genetic mutation passed from a father to his daughter on the X-chromosome that puts her at higher risk for ovarian cancer. The research team is looking for what the Ovarian Cancer gene looks like. (WBZ-TV) When we think of hereditary ovarian cancer, we often think of the BRCA genes that raise the risk of both ovarian cancer and breast cancer in first degree female relatives,...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 22, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Seen On WBZ-TV Syndicated Local Cancer Risk Dr. Mallika Marshall Genes ovarian cancer Source Type: news

Some Outcomes Not Necessarily Better With Robotic Prostate Surgery Some Outcomes Not Necessarily Better With Robotic Prostate Surgery
Men with prostate cancer who get the gland removed may be just as likely to suffer erectile dysfunction and urinary incontinence with robotic surgery as with other operations, a UK study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer
Decipher testing recognized as standard-of-care in management of prostate cancer patients SAN DIEGO, Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced tha... Diagnostics, Oncology GenomeDx Biosciences, NCCN, Decipher Prostate, Prostate Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

After-effects not necessarily reduced with robotic prostate surgery
(Reuters Health) - Men with prostate cancer who get the gland removed may be just as likely to suffer after-effects like erectile dysfunction and urinary incontinence with robotic surgery as with other operations, a UK study suggests. (Source: Reuters: Health)
Source: Reuters: Health - February 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Perceived Narrowing of Racial Disparity in Prostate Cancer Outcomes Due to Screening
The observed narrowing of racial disparities in prostate cancer outcome since the advent of PSA screening is not as large as previously believed. (Source: CancerNetwork)
Source: CancerNetwork - February 21, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers News Prostate Cancer Source Type: news

ERLEADA (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, available for order at Biologics, Inc.
CARY, N.C. (February 21, 2018) —Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, has been selected by the Janssen Pharmaceutical Companies of Johnson& Johnson1  to be in the limited distribution network for ERLEADA™ (apalutamide), the first FDA-approv... (Source: McKesson News)
Source: McKesson News - February 21, 2018 Category: Information Technology Source Type: news

Blue Earth touts addition of Axumin to NCCN guidelines
Blue Earth Diagnostics said that its Axumin (fluciclovine F-18) PET radiopharmaceutical...Read more on AuntMinnie.comRelated Reading: Blue Earth highlights Axumin clinical results at ASTRO Blue Earth touts Axumin reader training results Novel PET tracer aids recurrent prostate cancer patients Medicare coverage gets easier for oncologic PET tracers Blue Earth PET radiotracer IDs prostate cancer recurrence (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 20, 2018 Category: Radiology Source Type: news

Prostate cancer symptoms: Are you more likely to get disease with an enlarged prostate?
CANCER symptoms can be difficult to detect, particularly in the early stages. An enlarged prostate can sometimes be mistaken as a sign of prostate cancer - but does having an enlarged prostate mean you ’re more likely to get the deadly disease? (Source: Daily Express - Health)
Source: Daily Express - Health - February 19, 2018 Category: Consumer Health News Source Type: news

FDA Approves First Treatment for Nonmetastatic CRPC
The US Food and Drug Administration (FDA) has approved the oral agent apalutamide (Erleada) for the treatment of nonmetastatic castration-resistant prostate cancer. The oral androgen-receptor inhibitor is the first FDA-approved treatment for patients with nonmetastatic castration-resistant disease and the first to be approved based on the endpoint of metastasis-free survival. (Source: CancerNetwork)
Source: CancerNetwork - February 16, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Editorial Men ' s Health Prostate Cancer Source Type: news

Genetic mutation from father may speed onset of ovarian cancer
A genetic mutation linked to ovarian and prostate cancers and passed through the X-chromosome, has been identified, researchers announced. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 16, 2018 Category: Consumer Health News Source Type: news

Prostate cancer - how to test for the disease and what to expect when you see a GP
PROSTATE cancer symptoms include urinating more often than usual and feeling like your bladder isn ’t ever entirely empty. You should always see a doctor if you’re showing signs of the cancer, but what should you expect, and how can you test for prostate cancer? (Source: Daily Express - Health)
Source: Daily Express - Health - February 16, 2018 Category: Consumer Health News Source Type: news

Dad Can Pass on Ovarian Cancer Genes, Too
FRIDAY, Feb. 16, 2018 -- A gene mutation that's passed down from a father is associated with earlier onset of ovarian cancer in daughters and prostate cancer in the father and his sons, a new study suggests. Previous research had shown that sisters... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 16, 2018 Category: General Medicine Source Type: news

Medical News Today: Ovarian cancer: How your father's genes can affect your risk
New research finds that fathers can pass their daughters a genetic mutation that can cause ovarian cancer. It can also cause prostate cancer in men. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 16, 2018 Category: Consumer Health News Tags: Ovarian Cancer Source Type: news

New Treatment Approved for Prostate Cancer That Resists Hormone Therapy
Title: New Treatment Approved for Prostate Cancer That Resists Hormone TherapyCategory: Health NewsCreated: 2/14/2018 12:00:00 AMLast Editorial Review: 2/15/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 15, 2018 Category: Cancer & Oncology Source Type: news

New mutation linked to ovarian cancer can be passed down through dad
(PLOS) A newly identified mutation, passed down through the X-chromosome, is linked to earlier onset of ovarian cancer in women and prostate cancer in father and sons. Kunle Odunsi, Kevin H. Eng and colleagues at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., report these findings Feb. 15, 2018, in PLOS Genetics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 15, 2018 Category: Cancer & Oncology Source Type: news

ERLEADA ™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 15, 2018 Category: Pharmaceuticals Source Type: news

This Is the Link Between Processed Foods and Cancer
Processed snacks, drinks and desserts may be associated with a higher risk of cancer, according to a new study. The research, published Wednesday in The BMJ, focused on ultra-processed foods, which tend to be high in fat, saturated fat, sugar and salt. (Past research has found that Americans get 61% of their calories from highly processed foods.) In the new study, researchers found that, among almost 150,000 French adults, a 10% increase in the proportion of ultra-processed foods in a person’s diet was correlated with a 12% higher risk of cancer. The paper is the first to explore the link between cancer and ultra-pro...
Source: TIME: Health - February 14, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Diet/Nutrition healthytime onetime Source Type: news

FDA Approves Apalutamide for Nonmetastatic Prostate Cancer FDA Approves Apalutamide for Nonmetastatic Prostate Cancer
This is the first approved therapy for prostate cancer patients who have nonmetastatic, castration-resistant prostate cancer.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Drug to Help Curb a Tough - to - Treat Prostate Cancer
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 14, 2018 Category: Cancer & Oncology Tags: Nursing, Oncology, Pharmacy, Reproductive Medicine, Research, News, Source Type: news

FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer
February 14, 2018 -- The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 14, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves J & J prostate cancer treatment
(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Johnson& Johnson's Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy. (Source: Reuters: Health)
Source: Reuters: Health - February 14, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
FDA approves Erleada (apalutamide), first treatment for non-metastatic, castration-resistant prostate cancer (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 14, 2018 Category: American Health Source Type: news

New Treatment Apalutamide (Erleada) Approved for Prostate Cancer That Resists Hormone Therapy
WEDNESDAY, Feb. 14, 2018 -- Erleada (apalutamide) has been approved by the U.S. Food and Drug Administration to treat non-spreading prostate cancer that continues to grow despite hormone therapy. Prostate cancer is the second-most-common form of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 14, 2018 Category: General Medicine Source Type: news

New Treatment Approved for Prostate Cancer That Resists Hormone Therapy
WEDNESDAY, Feb. 14, 2018 -- Erleada (apalutamide) has been approved by the U.S. Food and Drug Administration to treat non-spreading prostate cancer that continues to grow despite hormone therapy. Prostate cancer is the second-most-common form of the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 14, 2018 Category: General Medicine Source Type: news

FDA Approves Apalutamide (Erleada) to Help Curb a Tough-to-Treat Prostate Cancer
WEDNESDAY, Feb. 14, 2018 -- A new drug that can stall the progression of a particularly hard-to-treat form of prostate cancer has been approved for use by U.S. health officials. In a recent study, the drug called Erleada (apalutamide) has shown... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 14, 2018 Category: General Medicine Source Type: news

FDA Approves Drug to Help Curb a Tough-to-Treat Prostate Cancer
WEDNESDAY, Feb. 14, 2018 -- A new drug that can stall the progression of a particularly hard-to-treat form of prostate cancer has been approved for use by U.S. health officials. In a recent study, the drug called Erleada (apalutamide) has shown... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 14, 2018 Category: General Medicine Source Type: news

Only U.S. Cryotherapy Trial for Mesothelioma Finds Success
Thoracic surgeon Dr. Shanda Blackmon at the Mayo Clinic in Rochester, Minnesota, believes there is a place for cryotherapy in the future multidisciplinary treatment of pleural mesothelioma. She wants to show it with this groundbreaking clinical trial. “We think [cryotherapy] could play an important role in treatment,” Blackmon told Asbestos.com. “So far, things look promising, but you can’t say anything specific without more numbers. Right now, it’s a little like telling a story.” Cryotherapy involves destroying cancer cells, or any abnormal tissues, by freezing them with controlled nitr...
Source: Asbestos and Mesothelioma News - February 14, 2018 Category: Environmental Health Authors: Daniel King Tags: ADI-PEG 20 cryoablation cryotherapy intrapleural measles virus Mayo Clinic mesothelioma clinical trial Opdivo pacific mesothelioma center pleural mesothelioma pleuroscopy Shanda Blackmon Surgery for Mesothelioma After Radiation Thera Source Type: news

Imaging Agent Can Change Plans for Recurrent Prostate Cancer Imaging Agent Can Change Plans for Recurrent Prostate Cancer
Clinicians viewing scans using the imaging agent 18F-fluciclovine changed their management plans in 61% of cases of biochemical recurrence of prostate cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Prostate cancer - Add these FIVE foods to your diet to slash your risk of deadly disease
PROSTATE cancer symptoms don ’t usually show until the disease has reached its latter stages, but can include a weak flow of urine and difficulty starting to urinate. You could lower your risk of the cancer by adding these foods to your diet. (Source: Daily Express - Health)
Source: Daily Express - Health - February 13, 2018 Category: Consumer Health News Source Type: news

Criteria for Prostate Cancer Trials Disproportionately Exclude Blacks
Trials sponsored by academic investigators, cooperative groups more likely to use these criteria (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 12, 2018 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Urology, Journal, Source Type: news

Prostate Cancer Immunotherapy Prostate Cancer Immunotherapy
Find out more about the current landscape for prostate cancer immunotherapy and learn about potential treatment strategies.Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Black men more likely to be excluded from cancer trials
Researchers at The Brigham and Women's Hospital found black men are more likely to be excluded from prostate cancer trials despite having a higher risk of developing the disease. (Source: the Mail online | Health)
Source: the Mail online | Health - February 9, 2018 Category: Consumer Health News Source Type: news

New prostate cancer drugs can give an extra 2 years to men
International trials of new drugs conducted in part by Northwestern University and Massachusetts General both succeeded in delaying the excruciating and deadly spread of prostate cancer in men. (Source: the Mail online | Health)
Source: the Mail online | Health - February 9, 2018 Category: Consumer Health News Source Type: news

Longer Endocrine Tx Better in Prostate Cancer
(MedPage Today) -- No survival advantage adding bisphosphonate in final RADAR results (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 9, 2018 Category: Hematology Source Type: news

Two Drugs Offer Hope Against a Tough-to-Treat Prostate Cancer
Title: Two Drugs Offer Hope Against a Tough-to-Treat Prostate CancerCategory: Health NewsCreated: 2/8/2018 12:00:00 AMLast Editorial Review: 2/9/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 9, 2018 Category: Cancer & Oncology Source Type: news

ERLEADA ™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 9, 2018 Category: Pharmaceuticals Source Type: news

Apalutamide Active in Castration - Resistant Prostate Cancer
Apalutamide prolongs metastasis - free survival in non - metastatic castration - resistant prostate cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 9, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Conference News, Source Type: news

Two Drugs Offer Hope Against Prostate Cancer
Two cancer drugs can stall the progression of a particularly hard-to-treat form of prostate cancer, a pair of new trials shows. (Source: WebMD Health)
Source: WebMD Health - February 9, 2018 Category: Consumer Health News Source Type: news

Two Drugs Offer Hope Against a Tough-to-Treat Prostate Cancer
(Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - February 9, 2018 Category: Cancer & Oncology Source Type: news

Zytiga (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
HORSHAM, PA, Feburary 8, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga (abiraterone acetate) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 8, 2018 Category: Drugs & Pharmacology Source Type: news

Two Prostate Cancer Drugs Delay Spread of the Disease by Two Years
The treatments could help hundreds of thousands of men worldwide stave off pain and chemotherapy, but researchers don ’ t yet know if they will extend lives. (Source: NYT Health)
Source: NYT Health - February 8, 2018 Category: Consumer Health News Authors: PAM BELLUCK Tags: Prostate Cancer Source Type: news

Two Drugs (#Apalutamide and #Enzalutamide) Offer Hope Against a Tough-to-Treat Prostate Cancer
THURSDAY, Feb. 8, 2018 -- Two cancer drugs can stall the progression of a particularly hard-to-treat form of prostate cancer, a pair of new trials shows. Both a newly developed drug called apalutamide and an already approved drug called... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 8, 2018 Category: General Medicine Source Type: news

ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
New indication for ZYTIGA® in combination with prednisone provides treatment option for patients with metastatic high-risk castration-sensitive prostate cancer Findings from pivotal Phase 3 LATITUDE clinical trial data demonstrated statistically sig... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, ZYTIGA, abiraterone, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2018 Category: Pharmaceuticals Source Type: news

ZYTIGA ® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

Genetic gene mutations: Opening new therapeutic avenues in metastatic prostate cancer
(Vall d'Hebron Institute of Oncology) International study shows the prognostic and predictive value of DNA-repair gene mutations in more precisely selecting standard therapies for the treatment of metastatic prostate cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2018 Category: International Medicine & Public Health Source Type: news

Black patients more likely to be excluded from prostate cancer trials
(Brigham and Women's Hospital) Study finds nearly half of all prostate cancer randomized clinical trials use lab results that are more likely to exclude black patients due to racial variations in laboratory values. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2018 Category: International Medicine & Public Health Source Type: news

Apalutamide delays progression of nonmetastatic, castration-resistant prostate cancer
(Massachusetts General Hospital) A multi-institutional phase 3 trial led by investigators at Massachusetts General Hospital and University of California, San Francisco found that treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 8, 2018 Category: Cancer & Oncology Source Type: news